Production, supply of single batch of Covaxin takes 120 days, says Bharat Biotech amid vaccine shortage

For vaccines to result in actual vaccination of people, the company said highly coordinated efforts are required from international supply chains, manufacturers, regulators, and state and central government agencies

Press Trust of India May 29, 2021 08:31:21 IST
Production, supply of single batch of Covaxin takes 120 days, says Bharat Biotech amid vaccine shortage

Representational image

Amid rising demand for COVID vaccines, Bharat Biotech on Friday said production and supply of Covaxin is a time-consuming process as various procedures and approvals need to be in place before it is made available for vaccination.

The Hyderabad-based vaccine major noted the timeline for manufacturing, testing and release for a batch of Covaxin is around 120 days, depending on the technology framework and regulatory guidelines to be met.

The company's statement comes amid shortage of COVID jabs in the country and demand from various states to enhance the production of vaccines.

"Thus, production batches of Covaxin that were initiated during March this year will be ready for supply only during the month of June," it said in a statement, adding that manufacturing, testing, release and distribution of vaccines is a complex and multi-factorial process with hundreds of steps, requiring a diverse pool of human resources.

For vaccines to result in actual vaccination of people, the company said highly coordinated efforts are required from international supply chains, manufacturers, regulators, and state and central government agencies.

"Production scale-up of vaccines is a step-by-step process, involving several regulatory SOPs of GMP (Standard Operating Procedures of Good Manufacturing Practices). There is a four-month lag time for Covaxin to translate into actual vaccination," it noted.

The company said that based on Central Drugs Standard Control Organisation (CDSCO) guidelines, all vaccines supplied in India are mandated by law to be submitted for testing and release to the Central Drugs Laboratory.

All batches of vaccines supplied to state and central governments are based on the allocation framework received from the central government, the company said, adding that the timeline for vaccine supplies to reach the depots of the state and central governments from the company's facilities is around two days.

The vaccines received at these depots have to be further distributed by the state governments to various districts within their respective states and thus requires an additional number of days, it noted.

"Pandemic vaccines are distributed by respective governments equitably across all sections of the population. Vaccines once available at the vaccination centres are then administered to recipients over a period of time, based on demand," it added.

With the increase in demand, Bharat Biotech has already taken steps to produce additional 200 million (20 crore) doses of Covaxin at its subsidiary's Gujarat-based facility. This will take the overall production volume to about 1 billion (100 crore) doses per annum.

From 1 May, the government started COVID vaccination drive for population above 18 years of age. The procurement of vaccines for those between 18 and 44 years has been left to states and private hospitals. This has led to state after state rushing to Bharat Biotech and Serum Institute of India (SII) for supply of vaccines.

Updated Date:

also read

COVID-19 updates: Bihar, Lakshadweep, Assam ease curbs; Amarnath Yatra cancelled for second year straight
India

COVID-19 updates: Bihar, Lakshadweep, Assam ease curbs; Amarnath Yatra cancelled for second year straight

The Assam government eased lockdown-like restrictions in eight districts but warned that in may impose stricter curbs in some other districts if the situation does not improve

SII may roll out Novavax's Covovax COVID-19 vaccine by Sept; key updates on India's vaccine drive
India

SII may roll out Novavax's Covovax COVID-19 vaccine by Sept; key updates on India's vaccine drive

Novavax said that the efficacy of its vaccine was 93.2 percent against Variants of Concern (VoC) and Variants of Interest (VoI), which represented 82 percent of the cases during trials

Why WHO assessment of safety and efficacy is essential for Covaxin to get nod for global emergency use
India

Why WHO assessment of safety and efficacy is essential for Covaxin to get nod for global emergency use

WHO has said that a COVID-19 vaccine should at least show the efficacy of 50 percent in mandated trials and Covaxin clears this requirement with its latest Phase-3 results